Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
PMV Pharmaceuticals (PMVP): Shares Pull Back 6% as Rezatapopt Moves Toward Regulatory Milestone

PMV Pharmaceuticals (PMVP): Shares Pull Back 6% as Rezatapopt Moves Toward Regulatory Milestone

Key Takeaways

  • PMVP shares trade near $1.25, roughly 6% lower over the trailing 30 days, after a sharp early-October rally pulled back.
  • PMV Pharmaceuticals is a precision oncology company focused on small-molecule therapies that target p53, a key tumor-suppressor protein.
  • Updated Phase 2 PYNNACLE data showed a 46% overall response rate for rezatapopt in platinum-resistant/refractory ovarian cancer.
  • Management plans to submit a New Drug Application (NDA) for accelerated approval of rezatapopt in the first quarter of 2027.
  • The company held $79.4 million in cash and equivalents as of June 30, 2026, providing expected runway into the second quarter of 2027.

Market Snapshot for PMVP

PMV Pharmaceuticals trades in the low single digits, typical for a clinical-stage biotech where valuation hinges more on pipeline milestones than current revenue. Over the trailing 30 days, the stock has declined roughly 6%, settling near $1.25 after an early-October surge that briefly carried shares toward the $1.90 level. The pullback reflects profit-taking and the usual volatility of a micro-cap name with no commercial products, even as the lead program advances toward a major regulatory catalyst.

Broader sentiment in the small-cap biotechnology segment has remained mixed, with investor attention concentrated on clinical readouts and financing dynamics. For PMVP, the dominant narrative is the regulatory path for rezatapopt, which continues to anchor both the stock’s upside potential and its near-term risk profile. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

PMV Pharmaceuticals Business Overview and Competitive Position

PMV Pharmaceuticals is a precision oncology company headquartered in Princeton, New Jersey, pioneering small-molecule therapies targeting p53, a well-known tumor-suppressor protein often described as the “guardian of the genome.” The company was co-founded by Dr. Arnold Levine, who discovered the p53 protein in 1979. Because TP53 mutations are found in roughly half of all cancers, restoring p53 function represents a broad and largely underexploited therapeutic opportunity.

The company’s lead candidate, rezatapopt (PC14586), is a first-in-class, orally administered p53 reactivator designed to selectively bind to the pocket created by the Y220C mutation, restoring wild-type tumor-suppressor function. It is being evaluated in the registrational Phase 2 portion of the PYNNACLE trial across ovarian, lung, breast, endometrial, and other solid tumors. The FDA has granted rezatapopt Fast Track designation for locally advanced or metastatic solid tumors with a p53 Y220C mutation, as well as Orphan Drug Designation for TP53 Y220C-positive ovarian, fallopian tube, and primary peritoneal cancers.

Recent Developments Driving PMVP

The most consequential catalyst has been the clinical progress of rezatapopt. In late August 2026, PMV reported updated interim data from the Phase 2 pivotal portion of PYNNACLE, showing an overall response rate of 46% (35 of 76 evaluable patients) in platinum-resistant/refractory ovarian cancer, including four confirmed complete responses. The median duration of response among confirmed responders reached 10.0 months, with a favorable and consistent safety profile and a low discontinuation rate.

Regulatory momentum has also advanced. PMV stated that recent FDA feedback supports its strategy to pursue accelerated approval for rezatapopt in platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation, with an NDA submission planned for the first quarter of 2027. Separately, the company raised capital to support development, and a warrant offering was structured around the NDA acceptance milestone, underscoring how closely investor risk is tied to the regulatory path. From what I see, this timeline remains the key focus for the stock.

Corporate governance changes rounded out the period, including the appointment of Laurie Stelzer as Board Chair in mid-2026 and the addition of healthcare investor Matt Eckler, Ph.D., to the board in October 2026. I looked at recent price action patterns using Tickeron’s AI Real Time Patterns to put the volatility in context.

2026 Outlook and What Investors Should Watch

Looking ahead, the central event for PMV Pharmaceuticals is the planned NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer during the first quarter of 2027, preceded by a full Phase 2 PYNNACLE data update expected at a medical conference in the fourth quarter of 2026. Investors will be watching the durability of responses, the safety profile, and any additional FDA communication on the accelerated-approval pathway.

Financial sustainability is another key theme. With $79.4 million in cash as of mid-2026 and a stated runway into the second quarter of 2027, additional capital raises could influence share count and investor sentiment. Analyst commentary has included maintained Buy and Outperform ratings with price targets around $5, though ratings reflect independent views and are subject to change. The company’s next quarterly earnings report, scheduled for November 2026, will provide updated financials and pipeline guidance. As with all clinical-stage biotechnology, regulatory outcomes, clinical data, and financing conditions remain the primary sources of risk.

Exploring AI Tools for Biotech Analysis

In my own research process, I’ve found Tickeron’s Trending AI Robots helpful for spotting automated strategies that align with biotech volatility. The page surfaces top-performing bots across thousands of tickers, letting users filter by approach and performance metrics. It’s one way I cross-check ideas without replacing my own due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PMVP

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


PMVP in +5.34% Uptrend, advancing for three consecutive days on November 03, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PMVP advanced for three days, in 206 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PMVP as a result. In 83 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

The Moving Average Convergence Divergence Histogram (MACD) for PMVP turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

PMVP moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PMVP crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMVP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for PMVP entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.942) is normal, around the industry mean (3.586). P/E Ratio (-0.887) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. PMVP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMVP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
400 Alexander Park Drive
Phone
+1 609 642-6670
Employees
54
Web
https://www.pmvpharma.com
Interact to see
Advertisement
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.